← All workflows

Pharma Reg Summary

Pharma Regulatory Summaries in Minutes, Not Hours

12 minutes with CaseMark

Fast lane

We have it from here.

Choose the fast one-off run here, or jump into the workspace when you want saved history, revisions, and a fuller matter workflow.

Run this once here

Best for a quick one-off job. Add your email, upload the files, and we'll run the workflow and send the result to your inbox.

1. Add your email so we know where to send the result.

2. Upload the files you want analyzed.

3. Run the workflow and we'll take it from there.

Use in Workspace

Best for ongoing matters

Save and reopen matters, keep documents together, refine the output, rerun with changes, and export or share polished work product when you're done.

Open in Workspace

Need more context?

Scroll for the workflow details below if you want to review what this run handles, what documents help, and what the output looks like.

If this is part of a live matter, the workspace is the better fit: you can keep your documents together, revisit the result, and keep working without starting from scratch.

Jump to detailsOpen in Workspace

Start here

Run this workflow now

Best for a fast one-off run. Add your email, upload the files, and we'll deliver the result without sending you into the full app.

Workflow

Pharma Reg Summary

Step 1 · Deliver to

Step 3 · Run this workflow

Workflow

Pharma Reg Summary

Overview

CaseMark's Pharmaceutical Regulatory Compliance Summary skill transforms complex FDA regulatory landscapes into structured, actionable compliance overviews. It systematically analyzes drug approval pathways, patent and IP intersections, and marketing compliance obligations to deliver comprehensive summaries that would traditionally require days of manual regulatory research. Whether you're preparing for an FDA submission, assessing post-market obligations, or reviewing promotional compliance, this skill provides the structured framework your regulatory and legal teams need.

Pharmaceutical regulatory compliance spans an enormous landscape—from FDA approval pathways and post-market safety obligations to Orange Book patent listings and Anti-Kickback Statute requirements. Manually compiling comprehensive compliance summaries requires cross-referencing dozens of regulatory frameworks, tracking evolving guidance documents, and synthesizing information across legal, regulatory, and commercial teams. This process is time-intensive, error-prone, and often results in incomplete or inconsistent assessments.

CaseMark automates the creation of structured pharmaceutical regulatory compliance summaries by analyzing your regulatory filings, product portfolio, and compliance records against established FDA frameworks. The AI generates organized, citation-rich summaries covering drug approval pathways, patent/IP regulatory intersections, and marketing compliance—complete with per-product checklists and risk flags—enabling your team to focus on strategic decision-making rather than manual document compilation.

How it works

  1. 1. Upload your regulatory filings, product portfolio documents, and compliance records

  2. 2. AI analyzes FDA pathways, patent intersections, and promotional compliance requirements

  3. 3. Review the structured compliance summary with per-product checklists and risk flags

  4. 4. Export the finalized regulatory summary in your preferred format (DOCX, PDF)

What you get

  • Drug Approval & Post-Market Obligations Summary

  • Patent & IP Regulatory Intersections Analysis

  • Marketing & Promotional Compliance Review

  • Per-Product Compliance Checklists

  • Risk Assessment & Remediation Recommendations

What it handles

  • Structured FDA approval pathway analysis across NDA, ANDA, and BLA submissions

  • Patent and IP regulatory intersection mapping including Orange Book and exclusivity periods

  • Marketing and promotional compliance review for off-label, DTC, and Anti-Kickback risks

  • Post-market obligation tracking with PMR/PMC deadlines and escalation triggers

  • Per-product compliance checklists covering IND, data integrity, and FAERS reporting

  • Hatch-Waxman framework analysis with Paragraph IV certification assessment

Required documents

  • Regulatory Filings

    Pending or approved NDAs, ANDAs, BLAs, active INDs, and related FDA submission documents

    .pdf, .docx

  • Product Portfolio Documentation

    Product listings, pipeline compounds, therapeutic area classifications, and patent/exclusivity records

    .pdf, .docx, .xlsx

  • Compliance and Commercial Records

    Warning letters, consent decrees, audit findings, speaker program records, and DTC campaign materials

    .pdf, .docx

Supporting documents

  • Orange Book Listings

    Current Orange Book patent and exclusivity listings for relevant products

    .pdf, .xlsx

  • Post-Market Commitment Tracker

    PMR/PMC status reports, REMS documentation, and FAERS reporting logs

    .pdf, .docx, .xlsx

  • Promotional Review Materials

    Marketing materials, promotional pieces, and prior OPDP/APLB correspondence

    .pdf, .docx

Why teams use it

Dramatically reduce the time spent compiling regulatory compliance summaries from days to minutes

Ensure comprehensive coverage across all three critical compliance domains: FDA approvals, patent/IP strategy, and promotional compliance

Generate per-product compliance checklists with specific regulatory citations and deadline tracking

Identify potential compliance gaps and risk areas before they become enforcement actions or warning letters

Questions

What types of FDA approval pathways does this skill cover?

CaseMark's pharma regulatory summary covers all major FDA pathways including NDA 505(b)(1), ANDA 505(j), BLA 351(a), and expedited pathways such as Breakthrough Therapy, Fast Track, and Accelerated Approval. Each pathway is analyzed with specific requirements and common pitfalls.

Can this tool handle both branded and generic pharmaceutical compliance?

Yes. CaseMark analyzes compliance considerations for both branded (NDA) and generic (ANDA) products, including Hatch-Waxman provisions, Paragraph IV certifications, Orange Book listings, and exclusivity periods that affect both originator and generic manufacturers.

How does the skill address promotional and marketing compliance?

CaseMark evaluates your commercial activities against off-label promotion rules, DTC advertising requirements, Anti-Kickback Statute provisions, and speaker program compliance. The output flags potential risk areas and provides actionable guidance for remediation.

Is this suitable for submission readiness assessments?

Absolutely. CaseMark generates per-product compliance checklists covering IND requirements, data integrity under 21 CFR Part 11, post-market safety reporting obligations, and PMR/PMC tracking—giving you a clear picture of submission readiness gaps.

How current is the regulatory framework analysis?

CaseMark's analysis is built on established FDA regulatory frameworks including 21 CFR 312, 21 CFR 314, and related guidance documents. While it provides comprehensive structural analysis, teams should verify against the latest FDA guidance updates for any recent regulatory changes.

Can I use this for international pharmaceutical compliance?

CaseMark's primary focus is FDA and U.S. regulatory compliance, but the summary also addresses PSUR/PBRER requirements for internationally marketed products. For comprehensive global regulatory analysis, the output serves as a strong U.S. compliance foundation to complement international assessments.

Related

30b6 Corporate Rep

Draft & Defend 30(b)(6) Depositions in Minutes

30b6 Deposition

Master 30(b)(6) Depositions in Minutes, Not Hours

Abstract of Judgment

Draft Judgment Abstracts in Minutes, Not Hours